GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Woojung Bio Inc (XKRX:215380) » Definitions » Debt-to-Asset

Woojung Bio (XKRX:215380) Debt-to-Asset : 0.53 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Woojung Bio Debt-to-Asset?

Woojung Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩26,115 Mil. Woojung Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩26,201 Mil. Woojung Bio's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was ₩98,333 Mil. Woojung Bio's debt to asset for the quarter that ended in Dec. 2023 was 0.53.


Woojung Bio Debt-to-Asset Historical Data

The historical data trend for Woojung Bio's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Woojung Bio Debt-to-Asset Chart

Woojung Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.14 0.36 0.39 0.43 0.53

Woojung Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.52 0.53 0.53 0.53

Competitive Comparison of Woojung Bio's Debt-to-Asset

For the Biotechnology subindustry, Woojung Bio's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Woojung Bio's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Woojung Bio's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Woojung Bio's Debt-to-Asset falls into.



Woojung Bio Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Woojung Bio's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(26115.463 + 26200.546) / 98332.604
=0.53

Woojung Bio's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(26115.463 + 26200.546) / 98332.604
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Woojung Bio  (XKRX:215380) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Woojung Bio Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Woojung Bio's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Woojung Bio (XKRX:215380) Business Description

Traded in Other Exchanges
N/A
Address
Gwanggyo-ro 145, B-dong 3rd Floor, Next Generation Convergence Technology Research Center, Gyeonggi-do, Yeongtong-gu, Suwon-si, KOR
Woojung Bio Inc is engaged in the research and development of natural science and engineering. Its products include Gene Delivery, Antibody Production, Immunodeficiency model, Human-to-human model, Zika, Mers, Dengue, Influenza Virus Research, Influenza virus, vaccine studies, and Elegant Goettingen Mini Pig.

Woojung Bio (XKRX:215380) Headlines

No Headlines